Leuprorelin for children with central precocious puberty
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a monthly injection of leuprorelin to see if it can slow or stop early puberty in children with central precocious puberty. It may help children who start puberty too early grow at a more typical pace.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a girl under 9 years old or a boy under 10 years old
- You must have started puberty (Tanner stage 2 or more) earlier than normal
- You must have been diagnosed with central precocious puberty by a doctor
- You cannot have certain other types of early puberty (like from brain tumors or other causes)
- You cannot have liver or kidney problems
- You cannot have taken certain hormone-related medications or steroids in the last 8 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatment schedules of a puberty-blocking medicine (triptorelin) in children with central precocious puberty (early puberty). It aims to see if a 3-month injection works as well as the standard 1-month injection, while also checking effects on bone health and metabolism.
This Phase 2 study tests whether a monthly hormone medicine (leuprolide, a GnRH agonist given as an injection) can slow down ongoing, fast-growing polycystic livers. It is aimed at pre-menopausal women with very large livers that are still getting bigger on past and current scans.
This study looks at children with central precocious puberty (early puberty that starts in the brain) to see how often it's linked with other developmental issues. It compares how these children develop and respond to treatment.
This study looks at a simpler blood test to diagnose early puberty in children. It checks if a single blood test can replace the longer, more complex stimulation test.
This study tests a new medicine called HHK001 for endometriosis. It is compared with a standard treatment (Enantone) to see if it is safe and works well to reduce symptoms.
This trial tests a study drug called endoxifen to see if it can help stop early puberty and vaginal bleeding in girls with McCune-Albright syndrome. It might help by blocking the effects of estrogen, the hormone that causes these symptoms.
Hear when a new Central Precocious Puberty trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.